

# Pharmacokinetics of a long-acting GLP-1 receptor agonist in minipigs

### **Authors**

Trine Porsgaard, Helene Kringel, Michael Christensen and Silas Rasmussen

Gubra, Hørsholm Kongevej 11B, Hørsholm, Denmark

### Corresponding author

Michael Christensen - mch@gubra.dk

# Background & Aim

Minipigs are increasingly applied in preclinical drug safety testing and for prediction of human pharmacokinetics (PK). Also, studies in minipigs are most cost-effective and have fewer ethical implications as compared to non-human primates.

The present study evaluated the PK of a proprietary, long-acting GLP-1 receptor agonist in minipigs to enable dose prediction in humans.


### Methods

See study outline. Female minipigs (n=3/group, 28-30 weeks of age and 14 kg at study start) were housed in Gubra's controlled minipig environment with tap water *ad libitum* and standard minipig diet (Altromin) being available twice a day.


Minipigs were dosed with the long-acting GLP-1 receptor agonist GUB021794 (2 nmol/kg), administered either as slow intravenously infusion (1 ml/kg, 5 min), or subcutaneous bolus (0.25 ml/kg).

Blood samples were collected from v. jugularis for up to 16 days post-dosing. Plasma samples were analysed using LC-MS/MS and PK parameters were estimated by non-compartmental analysis (NCA).

www.gubra.dk



# 2 Gubra workflow and capabilities



# 3 PK profile

# GUB021794 in Göttingen Minipigs dose\_route N SC dose\_route

**Figure 1. PK profile** in minipigs of Gubra's long-acting GLP-1 receptor agonist GUB021794 after a 5 min intravenous infusion or subcutaneous injection (2 nmol/kg, n=3). Each data point represents the geometric mean, and the error bars represent the geometric standard deviation.

# PK parameters

Parameter	Unit	GUB021794	
		IV infusion (5min)	SC bolus
Nominal Dose	nmol/kg	2	2
AUC <sub>inf</sub>	nmol.h/L	3230	2330
AUC <sub>last</sub>	nmol.h/L	2830	1900
%AUC <sub>extrapolated</sub>	%	13	18
T <sub>last</sub>	h	200	232
$C_{max}$	nmol/L	59	14.9
$T_{max}$	h	0.083	35
Cl	L/h/kg	0.00062	-
V <sub>ss</sub>	L/kg	0.055	-
t <sub>1/2</sub>	h	71	86
MRT	h	90	135
F	%		72

Figure 2. Calculated PK parameters in minipigs obtained by non-compartmental analysis. Abbreviations: AUC<sub>inf</sub>, area-under-the-curve from time of dosing extrapolated to infinity; %AUC<sub>extrapolated</sub>, percentage of the AUC being extrapolated; AUC<sub>last</sub>, area-under-the-curve from time of dosing to last measurable concentration,  $C_{max}$ , highest measured concentration; CI, total body clearance of the drug; F, calculated bioavailability of the SC route; MRT, mean residence time;  $T_{last}$ , timepoint of the last measurable concentration;  $T_{max}$ , time to maximum concentration;  $V_{ss}$ , volume of distribution at steady-state.;  $T_{1/2}$ , terminal half-life.

# Conclusion

- + Pharmacokinetics of long-acting GLP-1 receptor agonist (GUB021794) was successfully evaluated in minipigs
- + The long-acting GLP-1 receptor agonist is applicable for once-weekly dosing in humans
- Minipigs represent a suitable non-rodent species for clinical translation of peptide drug pharmacokinetics



Scan the QR code to learn more about our services within drug pharmacokinetics